首页> 外文期刊>Cellular Physiology and Biochemistry >Co-Upregulation of 14-3-3ζ and P-Akt is Associated with Oncogenesis and Recurrence of Hepatocellular Carcinoma
【24h】

Co-Upregulation of 14-3-3ζ and P-Akt is Associated with Oncogenesis and Recurrence of Hepatocellular Carcinoma

机译:14-3-3ζ和P-Akt的共同上调与肝细胞癌的发生和复发相关。

获取原文
           

摘要

Background/Aims 14-3-3ζ is involved in the regulation of PI3K/Akt pathway which is closely associated with carcinogenesis. However, the clinical significance of combined detection of 14-3-3ζ and p-Akt in hepatocellular carcinoma (HCC) remains unclear. Methods Two-hundred pairs of HCC and adjacent liver specimens were subjected to tissue microarray. The association of 14-3-3ζ and p-Akt levels with the postoperative survival and recurrence in HCC patients was analyzed with univariate and multivariate methods. Moreover, the effects of 14-3-3ζ overexpression on the growth of HCC and the expressions of p-Akt and HIF-1α were assessed in a xenograft mouse model. Results Elevated levels of 14-3-3ζ and p-Akt were detected in HCC and a positive correlation between the levels of 14-3-3ζ and p-Akt was verified. HCC patients with satellite nodules, microvascular invasion, portal vein tumor thrombosis, poor tumor differentiation and an advanced tumor stage tended to have higher levels of 14-3-3ζ and p-Akt. In addition, the postoperative 3-, 5-, and 7-year overall survival rates in HCC patients with 14-3-3ζhigh and p-Akthigh were significantly lower compared with those with 14-3-3ζlow and p-Aktlow, and the cumulative recurrence rate in HCC patients with 14-3-3ζhigh and p-Akthigh was significantly higher than that in those with 14-3-3ζlow and p-Aktlow. The multivariate Cox proportional hazard analysis indicated that concomitant upregulation of 14-3-3ζ and p-Akt was an independent factor that predicted poor survival and high recurrence in HCC patients. Furthermore, animal experiment showed that overexpression of 14-3-3ζ accelerated the growth of HCC xenograft tumors and induced the expressions of p-Akt and HIF-1α in vivo. Conclusion Co-upregulation of 14-3-3ζ and p-Akt predicts poor prognosis in patients with HCC, and 14-3-3ζ-induced activation of the Akt signaling pathway contributes to HCC progression.
机译:背景/目的14-3-3ζ参与PI3K / Akt通路的调节,而PI3K / Akt通路与致癌作用密切相关。然而,在肝细胞癌(HCC)中联合检测14-3-3ζ和p-Akt的临床意义尚不清楚。方法对两百对肝癌和邻近的肝标本进行组织芯片分析。使用单变量和多变量方法分析了14-3-3ζ和p-Akt水平与HCC患者术后生存和复发的相关性。此外,在异种移植小鼠模型中评估了14-3-3ζ过表达对HCC生长以及p-Akt和HIF-1α表达的影响。结果在肝癌中检测到14-3-3ζ和p-Akt水平升高,并证实14-3-3ζ和p-Akt水平呈正相关。伴有结节状结节,微血管浸润,门静脉肿瘤血栓形成,不良肿瘤分化和晚期肿瘤分期的HCC患者往往具有较高的14-3-3ζ和p-Akt水平。此外,高14-3-3ζ高和p-Aktlow的HCC患者术后3、5和7年总生存率显着低于14-3-3ζ低和p-Aktlow的HCC患者,并且高14-3-3ζ和p-Aktlow的HCC患者的累积复发率显着高于14-3-3ζ低和p-Aktlow的HCC患者。多元Cox比例风险分析表明14-3-3ζ和p-Akt的同时上调是预测HCC患者生存不良和高复发率的独立因素。此外,动物实验表明14-3-3ζ的过表达促进了HCC异种移植肿瘤的生长并诱导了p-Akt和HIF-1α的体内表达。结论14-3-3ζ和p-Akt的共同上调预示了肝癌患者的预后不良,并且14-3-3ζ诱导的Akt信号通路的激活有助于肝癌的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号